MHRA-NICE pathway opens for business – everything you need to know to get started
Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.
Blogs
Blog post list
Better data for better decisions
Sophie Cooper, senior scientific adviser at NICE, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care
Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.
Driving biosimilar adoption through collaboration
How a collaborative taskforce is helping increase the uptake of biosimilars within the health and care sector.
NICE’s prioritisation process explained – what healthtech developers need to know
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
5 tips to help get your healthtech product to market, fast
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
Page 1 of 12